Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to evaluate the neuroprotective effects of RYANODEX (dantrolene sodium) in nerve agent exposure

Trial Profile

A study to evaluate the neuroprotective effects of RYANODEX (dantrolene sodium) in nerve agent exposure

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs Dantrolene (Primary)
  • Indications Neurological disorders
  • Focus Therapeutic Use
  • Sponsors Eagle Pharmaceuticals
  • Most Recent Events

    • 11 Oct 2018 New trial record
    • 03 Oct 2018 According to an Eagle Pharmaceuticals media release, has entered into an agreement with the United States Army Medical Research Institute of Chemical Defense (USAMRICD) to conduct this study under Cooperative Research and Development Agreement (CRADA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top